December 17th 2024
The federal agency has set a target action date of June 10, 2025 for potential approval.
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
September 13th 2024The landmark indication is supported by a couple of pivotal trials assessing dupilumab for patients with chronic rhinosinusitis with nasal polyps, as well as a pediatric severe asthma trial assessing the biologic.
Boy presents with fatigue, minimal responsivity, and diffuse muscle weakness
August 7th 2024An 11-year-old boy with a history of asthma and allergic rhinitis presented to the emergency department (ED) with worsening fatigue, minimal responsivity to external stimuli, and diffuse muscle weakness for 2 months.
Communication, planning, and vaccines prevent infections in the school setting
July 16th 2024Donna Hallas. PhD, PPCNP-BC, CPNP, PMHS, FAANP, FAAN, underscores the critical need for proper vaccination and effective communication between parents and schools to ensure sick children stay home, while addressing logistical challenges faced by parents.